Patient participation is crucial to the successful completion of a trial, yet the barriers to trial participation – primarily ancillary costs – lie squarely on the shoulders of patients. In this video Lazarex Founder Dana Dornsife explains the iMPACT initiative.
Improving Patient Access to Cancer Clinical Trials
IMPACT is a 3-year nationwide program to increase cancer clinical trial enrollment, retention, minority participation and equitable access – getting cancer drugs to market faster and finishing oncology clinical trials on time and on budget.
Clinical trials are the vehicle the FDA
uses to bring new drugs to market safely. Patient participation is
crucial to the successful completion of a trial, yet the barriers to
trial participation – primarily ancillary costs – lie squarely on the
shoulders of patients. Over the past 10 years, Lazarex has developed
successful programs to address and remove these barriers. Currently,
Lazarex stands alone in offering a complete solution to this problem and
while this is a noble undertaking it is not a sustainable one.
In 2013 Lazarex and the Massachusetts General Hospital Cancer Care Equity Program joined forces to establish a pilot program focused on removing financial barriers to clinical trial participation for cancer patients and improving access to cancer clinical trials for under-served populations. Based on the success, we have greatly expanded the pilot into a nationwide effort – IMPACT – IMproving Patient Access to Cancer Clinical Trials. IMPACT brings together the significant resources of industry stakeholders: academia, medicine, policy makers, industry, public health and community organizations nationwide.
The IMPACT program facilitates a coordinated effort amongst these stakeholders to create a replicable, “boots on the ground” action plan, bringing significant and sustainable change to the status quo of clinical trial recruitment, retention, minority participation, completion, and translational science – providing equitable and timely patient access to cancer discovery.
Lazarex is featured on PBS Newshour: U.S. racial and ethnic diversity is ever increasing, but the medical representation of minority groups is not. A recent review of government-funded cancer research studies found that participants were disproportionately white, and fewer than 2 percent of these clinical trials focused on minorities specifically.
Watch the Video
October 9, 2019
“Lazarex stepped into the breach and recognized the big barriers — transportation and navigating the complexity of trials,” said Jonathan Jackson, founding director of Mass General’s center for research on trial diversity and inclusion. Lazarex “made it much easier for people to sign up and stick with a trial, and it helped marginalized populations.”
Read the Article
September 5, 2019
Development Manager Erin Miller sits down with AMGEN and The Washington Post Live to discuss IMPACT and clinical trials
Watch the Video
August 27, 2019
Lazarex VIP (Very Important Patient) Charmaine Sarpong and Founder Dana Dornsife speak with Fox 4 Dallas reporter Dionne Anglin about the legislation in Texas that is effective 9/1 and will help 10’s of thousands of the state’s cancer patients gain access to clinical trials. Texas is only the THIRD state (following CA and PA) to pass this law.
July 31, 2019
Leveling the Playing Field for Cancer Clinical Trials. Founding IMPACT sponsor, AMGEN, welcomes Lazarex Cancer Foundation’s Dana Dornsife to their headquarters campus.
June 18, 2019
Good Day DC Lazarex Cancer Foundation Interview: FOX 5’s Holly Morris sits down with Jackie Hinckley, a patient being helped by the Lazarex Cancer Foundation, and founder, Dana Dornsife
June 18, 2019
Disrupting the System ll: Lazarex Cancer Foundation hosted a roundtable discussion at the National Press Club in Washington DC.
June 18, 2019
Legislative Victory for Texas Cancer Patients: Lazarex Cancer Foundation applauds Texas lawmakers for passing a law to break barriers to cancer clinical trials and provide equal access to potentially life-saving breakthrough medical advancements
Read Press Release
June 10, 2019
Dr. Hala Borno on Addressing Disparities in Access to Prostate Cancer Care – Cancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer
Community, University, Industry Partner to Boost Minority Recruitment – A community-based initiative in West Philadelphia is blazing a trail for minority involvement in cancer trials, and academia and industry are signing on for the ride.
May 30, 2019
USC researchers offer financial aid to increase participation in clinical trials. Researchers depend on a wide variety of people signing up for clinical trials, so they can get the most diverse results. But participating in research can be time-consuming and costly
May 24, 2019
Drexel University is partnering with the Lazarex Cancer Foundation to establish Community IMPACT, a program that will focus on reducing cancer and improving health outcomes in Philadelphia. “We are committed to building healthy communities and giving voice to the voiceless and hope to the hopeless
Read Press Release
May 22, 2019
Social, cultural, and financial barriers pose a challenge in enrollment for oncology clinical trials, but USC investigator believes mitigating barriers to diversify research may provide comprehensive data.
May 21, 2019
Through offering financial reimbursement for travel and companion expenses, Lazarex Cancer Foundation has doubled and tripled minority participation in clinical trials
May 12, 2019
Dr. Kim Rhoads, Director of the UCSF Office of Community Engagement, and Dana Dornsife, founder of the Lazarex Cancer Foundation are guests on Fox KTVU’s Sunday’s Mornings on 2.
April 29, 2019
In collaboration with Lazarex Cancer Foundation, USC launches a 3-year IMPACT study focusing on reducing financial barriers to clinical trial enrollment for low-income and racial and ethnic minority cancer patients.
April 26, 2019
UC San Francisco collaborates with Lazarex Cancer Foundation on a three-year study to identify ways to improve cancer clinical trial participation among medically underserved populations, including low-income individuals and racial and ethnic minorities.
< Timeline >
December 10, 2018
The partnership between Amgen and Lazarex Cancer Foundation to support more equitable access to clinical trials for cancer patients in the U.S is announced.
October 17, 2018
Two major victories for cancer patients nationwide as bills promoting equal access to cancer trials become law: Congress and the state of Pennsylvania approve language aimed at increasing access among underserved communities. The inclusion of the language follows an intensive effort by Lazarex Cancer Foundation with members of congress and Pennsylvania state officials to bring this problem forward.
September 13, 2018
The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO would like to thank the Lazarex Cancer Foundation for funding the ASCO Roundtable on Addressing Financial Barriers to Clinical Trials Participation in 2017, which contributed to the development of this statement.
August 13, 2018
Massachusetts considers bill aimed at improving patient reimbursement for clinical trial expenses. Massachusetts is one of several states—including Texas, Pennsylvania and Florida—considering such legislation backed by California-based Lazerex Cancer Foundation to improve the ability of patients to enroll and remain enrolled in clinical trials. California passed a similar law in 2016.
May 8 & 9, 2018
Lazarex Cancer Foundation convenes 2 days of discussions with thought leaders in oncology, public health, private industry, patient advocacy and public policy to address clinical trials and data sharing.
January 25, 2018
The FDA issued revised guidance about reimbursement to clinical trial participants. The new guidance includes the following critical language and paves the way for industry funding for reimbursement of patient travel expenses: “FDA does not consider reimbursement for travel expenses to and from the clinical trial site and associated costs such as airfare, parking, and lodging to raise issues regarding undue influence.”
We initiate IMPACT CA with institutional partners UCSF Helen Diller Family Comprehensive Cancer Center and USC Norris Comprehensive Cancer Center.
< Timeline >
AMGEN signs on as the IMPACT Founding Sponsor with a $2 million grant to launch the IMPACT program.
< Timeline >
Governor Brown signs into law the California Cancer Clinical Trials Program. The new law will help increase patient enrollment, retention, and minority participation in cancer clinical trials, especially among women and under-represented communities.